Novavax reports positive phase 1 data on its Covid-19 vaccine candidate
Gaithersburg ’s Novavax Inc. (NASDAQ: NVAX) reported Tuesday positive phase 1 clinical trial data on its Covid-19 vaccine candidate, a necessary step to advance a product officials hope will eventually protect people from coronavirus.
The study found the candidate, called NVX-CoV2373, to both be generally wel l-tolerated and elicit “robust antibody responses,” the company said Tuesday, adding that it showed the potential to reduce the disease’s transmission.
Specifically, the candidate had…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Sara Gilgore Source Type: news
More News: Biotechnology | Clinical Trials | Coronavirus | COVID-19 | Health Management | Study | Vaccines